AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30817251 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG)
Number of subjects: 1297
Study 30817251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Arm P)
Number of subjects: 1297
Study 30817251 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (all groups)
Number of subjects: 1297
Study 29976247 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH and nutrition interventions delivered by Community Health Workers (CHWs)
Number of subjects: 4169
Study 29976247 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of CHW performance
Number of subjects: 4169
Study 27253216 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 30 min)
Number of subjects: 120
Study 27253216 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 120
Study 27253216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/d
Number of subjects: 120
Study 27253216 — intervention group
Group type: COMPARATOR
Intervention: Placebo sertraline
Number of subjects: 120
Study 24282136 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-degree reverse Trendelenburg position (5-RTP)
Number of subjects: 75
Study 24282136 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-degree reverse Trendelenburg position (10-RTP)
Number of subjects: 75
Study 24282136 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-degree reverse Trendelenburg position (20-RTP)
Number of subjects: 75
Study 24282136 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 5-RTP vs 20-RTP
Number of subjects: 75
Study 23171354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=171 workers)
Number of subjects: 293
Study 23171354 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=122 workers)
Number of subjects: 293
Study 20515580 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin (10 mg capsule orally per day)
Number of subjects: 60
Study 20515580 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (two 50 microg inhalations every 12 h)
Number of subjects: 60
Study 18831357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg)
Number of subjects: 30
Study 18831357 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 30
Study 18831357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15677776 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 70/30
Number of subjects: 233
Study 15677776 — intervention group
Group type: COMPARATOR
Intervention: Glargine
Number of subjects: 233
Study 12073665 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg bd and clarithromycin 500 mg bd for 14 days
Number of subjects: 137
Study 12073665 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg bd, clarithromycin 500 mg bd and amoxycillin 1 g bd for 7 days
Number of subjects: 137
Study 10091625 — intervention group
Group type: EXPERIMENTAL
Intervention: Write continuously for 30 min after btx A injection
Number of subjects: 8
Study 10091625 — intervention group
Group type: COMPARATOR
Intervention: Rest for 30 min after btx A injection
Number of subjects: 8
Study 10091625 — intervention group
Group type: EXPERIMENTAL
Intervention: Btx A treatment
Number of subjects: 8
Study 7789082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 564.5 mg/day as add-on therapy (plus CBZ)
Number of subjects: 34
Study 7789082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2128415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg PO 90 min before TRH)
Number of subjects: 22
Study 2128415 — intervention group
Group type: COMPARATOR
Intervention: TRH (200 micrograms IV bolus)
Number of subjects: 22
Study 371348 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexamethasone therapy (1 mg/kg) within six hours of injury, repeated at six hours, maintained at 1 mg/kg/day for eight days.
Number of subjects: 9
Study 371348 — intervention group
Group type: COMPARATOR
Intervention: None or low dose regimen (0.25 mg/kg/day).
Number of subjects: 9
Study 7093613 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-management training with positive self-statements
Number of subjects: 12
Study 7093613 — intervention group
Group type: COMPARATOR
Intervention: Anxiety-management training with negative self-statements
Number of subjects: 12
Study 31690303 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 60
Study 31690303 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure drainage (control)
Number of subjects: 60
Study 29427263 — intervention group
Group type: EXPERIMENTAL
Intervention: Parks with more amenities and features, fewer incivilities and reported crimes
Number of subjects: 1003
Study 29427263 — intervention group
Group type: COMPARATOR
Intervention: Parks closest to home
Number of subjects: 1003
Study 27245155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN) spray
Number of subjects: 27
Study 25313573 — intervention group
Group type: EXPERIMENTAL
Intervention: I40 - Basal diet supplemented with 40 mg Cu/kg DM in the form of copper sulphate
Number of subjects: 35
Study 25313573 — intervention group
Group type: EXPERIMENTAL
Intervention: O40 - Basal diet supplemented with 40 mg Cu/kg DM in the form of copper proteinate
Number of subjects: 35
Study 25313573 — intervention group
Group type: EXPERIMENTAL
Intervention: I10 - Basal diet supplemented with 10 mg Cu/kg DM in the form of copper sulphate
Number of subjects: 35
Study 25313573 — intervention group
Group type: EXPERIMENTAL
Intervention: O10 - Basal diet supplemented with 10 mg Cu/kg DM in the form of copper proteinate
Number of subjects: 35
Study 25313573 — intervention group
Group type: COMPARATOR
Intervention: Control - Basal diet without supplementation of Cu (7 mg Cu/kg DM)
Number of subjects: 35
Study 23055655 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation during colonoscopy
Number of subjects: 347
Study 20596795 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg suspension via NG/NJ tube daily
Number of subjects: 51
Study 20596795 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg IV q12 h
Number of subjects: 51
Study 20596795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 51
Study 20596795 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 51
Study 18046108 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/Hydrochlorothiazide (HCTZ) 300/25 mg
Number of subjects: 1235
Study 18046108 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 300 mg
Number of subjects: 1235
Study 18046108 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 1235
Study 16126936 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg acetazolamide
Number of subjects: 30
Study 16126936 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetazolamide
Number of subjects: 30
Study 16126936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12403212 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (1,000 ng/ml)
Number of subjects: 47
Study 12403212 — intervention group
Group type: COMPARATOR
Intervention: Control (without growth hormone)
Number of subjects: 47
Study 10090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (2 x 10(‐8) to 5 x 10(‐6) mol/L)
Number of subjects: 0
Study 10090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin‐1 (10(‐9) mol/L)
Number of subjects: 0
Study 10090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 10090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin‐1
Number of subjects: 0
Study 7761273 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI, 18FDG‐PET, and 99mTc‐HMPAO‐SPECT
Number of subjects: 51
Study 1969115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg per day
Number of subjects: 1338
Study 1969115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg per day
Number of subjects: 1338
Study 1969115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1338
Study 426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam premedication
Number of subjects: 0
Study 426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine premedication
Number of subjects: 0
Study 426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol formulation of etomidate
Number of subjects: 0
Study 426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene glycol formulation of etomidate
Number of subjects: 0
Study 426989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast injection with pethidine premedication
Number of subjects: 0
Study 426989 — intervention group
Group type: COMPARATOR
Intervention: Unpremedicated patients
Number of subjects: 0
Study 29153631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50mg
Number of subjects: 44
Study 29153631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 200mg
Number of subjects: 44
Study 29153631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 1000mg
Number of subjects: 44
Study 29153631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (all doses)
Number of subjects: 44
Study 29153631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50mg, 200mg
Number of subjects: 44
Study 29153631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (50-200mg)
Number of subjects: 44
Study 29153631 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (1.5mg, 3mg)
Number of subjects: 44
Study 29153631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29153631 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (4000mg)
Number of subjects: 44
Study 28324265 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF+T
Number of subjects: 90
Study 28324265 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 90
Study 26639477 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro emulsion formulation
Number of subjects: 360
Study 26639477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel formulation
Number of subjects: 360
Study 26639477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment formulation
Number of subjects: 360
Study 26639477 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulations
Number of subjects: 360
Study 23742877 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (6 mg/kg, intravenously every 3 weeks)
Number of subjects: 1224
Study 23742877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously every 3 weeks)
Number of subjects: 1224
Study 23742877 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 1224
Study 23742877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1224
Study 20130535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide treatment
Number of subjects: 25
Study 20130535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18375897 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 0
Study 18375897 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 0
Study 18375897 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18375897 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 0
Study 18375897 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus counseling group
Number of subjects: 0
Study 16538452 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 402
Study 14615734 — intervention group
Group type: EXPERIMENTAL
Intervention: Asphyxiated newborn infants
Number of subjects: 58
Study 14615734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 58
Study 14615734 — intervention group
Group type: COMPARATOR
Intervention: Control neonates
Number of subjects: 58
Study 10865186 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.S. (synthetic mixture of estrogens; 2 x 0.625 mg)
Number of subjects: 41
Study 10865186 — intervention group
Group type: COMPARATOR
Intervention: Premarin (2 x 0.625 mg)
Number of subjects: 41
Study 9354964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell wall‐associated proteins of Mycobacterium tuberculosis (SIHV) by ELISA
Number of subjects: 86
Study 9354964 — intervention group
Group type: COMPARATOR
Intervention: Control sera (healthy individuals)
Number of subjects: 86
Study 8397986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin bonding system that removed smear layer
Number of subjects: 44
Study 8397986 — intervention group
Group type: COMPARATOR
Intervention: Dentin bonding system that adhered to the dentin smear layer
Number of subjects: 44
Study 2871960 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (10 nmol/min)
Number of subjects: 7
Study 2871960 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 mg/kg, intravenously)
Number of subjects: 7
Study 2871960 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (10 mg, intravenously)
Number of subjects: 7
Study 2871960 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7
Study 30412061 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource mindfulness (test group)
Number of subjects: 50
Study 30412061 — intervention group
Group type: COMPARATOR
Intervention: Stress mindfulness (active control group)
Number of subjects: 50
Study 30412061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 26957418 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate stenting
Number of subjects: 140
Study 26957418 — intervention group
Group type: COMPARATOR
Intervention: Delayed stenting (DS)
Number of subjects: 140
Study 25686644 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (four weekly infusions of 375 mg/m(2))
Number of subjects: 313
Study 25686644 — intervention group
Group type: COMPARATOR
Intervention: Rituximab + interferon‐α2a (3‐4.5 MIU daily for 5 weeks)
Number of subjects: 313
Study 25686644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 313
Study 24821568 — intervention group
Group type: EXPERIMENTAL
Intervention: peramivir
Number of subjects: 191
Study 24821568 — intervention group
Group type: COMPARATOR
Intervention: zanamivir
Number of subjects: 191
Study 24821568 — intervention group
Group type: COMPARATOR
Intervention: oseltamivir
Number of subjects: 191
Study 24821568 — intervention group
Group type: COMPARATOR
Intervention: laninamivir
Number of subjects: 191
Study 20671033 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS-gated brachial artery diameter measurements
Number of subjects: 72
Study 20671033 — intervention group
Group type: COMPARATOR
Intervention: Average brachial diameters over the entire R-R interval
Number of subjects: 72
Study 18984252 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring severity score (SSS) = 4 or BMI = 26
Number of subjects: 211
Study 18984252 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > or = 32
Number of subjects: 211
Study 18984252 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS > or = 7
Number of subjects: 211
Study 16265663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa 7%
Number of subjects: 100
Study 16265663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12946731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 228
Study 12946731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 11061474 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg beclomethasone dipropionate
Number of subjects: 12
Study 11061474 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol
Number of subjects: 12
Study 11061474 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg salmeterol
Number of subjects: 12
Study 11061474 — intervention group
Group type: COMPARATOR
Intervention: 20 microg endotoxin (control)
Number of subjects: 12
Study 8742215 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 60
Study 8742215 — intervention group
Group type: COMPARATOR
Intervention: Surgical discectomy
Number of subjects: 60
Study 8742215 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (first-line treatment)
Number of subjects: 60
Study 1616080 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 24
Study 1616080 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesic therapy (intermittent intravenous morphine injections)
Number of subjects: 24
Study 6091483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g IV at start of anesthesia, followed by 1 g dose 24 hours later)
Number of subjects: 512
Study 6091483 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g IV at start of anesthesia, followed by 1.5 g every 12 hours for 2 days)
Number of subjects: 512
Study 6091483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g IV at start of anesthesia)
Number of subjects: 512
Study 30594365 — intervention group
Group type: EXPERIMENTAL
Intervention: 55,000 plants/ha
Number of subjects: 28
Study 30594365 — intervention group
Group type: EXPERIMENTAL
Intervention: 70,000 plants/ha
Number of subjects: 28
Study 30594365 — intervention group
Group type: EXPERIMENTAL
Intervention: 85,000 plants/ha
Number of subjects: 28
Study 30594365 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 plants/ha
Number of subjects: 28
Study 30594365 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing planting population
Number of subjects: 28
Study 30081667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-K Mathematics intervention
Number of subjects: 0
Study 26546051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct treatment with intravitreal and subtenons triamcinolone acetonide, oral flurbiprofen, and guttae prednisolone acetate 1%
Number of subjects: 40
Study 26546051 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 40
Study 26546051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct treatment
Number of subjects: 40
Study 24681717 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM (5-week computerized cognitive behavior therapy program)
Number of subjects: 0
Study 24681717 — intervention group
Group type: COMPARATOR
Intervention: Informational websites about mental health (control condition)
Number of subjects: 0
Study 22965622 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD prevention intervention arm
Number of subjects: 135
Study 22965622 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm focusing on increasing family cohesiveness, communication, and connectedness
Number of subjects: 135
Study 20060229 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge
Number of subjects: 60
Study 20060229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18044284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus administration of cisatracurium (Group A, n = 30)
Number of subjects: 60
Study 18044284 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of cisatracurium (Group B, n = 30)
Number of subjects: 60
Study 16047532 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 234
Study 16047532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 11896038 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (therapeutic dose)
Number of subjects: 0
Study 11896038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10426647 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 60
Study 10426647 — intervention group
Group type: COMPARATOR
Intervention: 600 microg misoprostol
Number of subjects: 60
Study 7760614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 197
Study 7760614 — intervention group
Group type: COMPARATOR
Intervention: Standard epidural analgesia
Number of subjects: 197
Study 1559504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil diet high in polyunsaturated fatty acids (13 E%, total fat 38%)
Number of subjects: 59
Study 1559504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet high in monounsaturated fatty acids (16 E%, total fat 38%)
Number of subjects: 59
Study 1559504 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet high in saturated fatty acids (19 E%, total fat 36%)
Number of subjects: 59
Study 1559504 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery period (4 weeks)
Number of subjects: 59
Study 4014617 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.75% in oxygen)
Number of subjects: 32
Study 4014617 — intervention group
Group type: COMPARATOR
Intervention: Entonox (50% nitrous oxide in oxygen)
Number of subjects: 32
Study 29947141 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) three times per week for 4 weeks
Number of subjects: 30
Study 29096877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 100
Study 29096877 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 100
Study 26514957 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted motivational intervention (CAMI)
Number of subjects: 572
Study 26514957 — intervention group
Group type: COMPARATOR
Intervention: Didactic educational counseling
Number of subjects: 572
Study 24607801 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current therapy (ICT)
Number of subjects: 42
Study 24607801 — intervention group
Group type: COMPARATOR
Intervention: Placebo-ICT
Number of subjects: 42
Study 22670827 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q SP
Number of subjects: 60
Study 22670827 — intervention group
Group type: COMPARATOR
Intervention: LMA-Unique
Number of subjects: 60
Study 20418006 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chest compressions (CCC)
Number of subjects: 64
Study 20418006 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR (30:2)
Number of subjects: 64